Jim Cramer Says “I Like AstraZeneca Very Much”

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are thinking of selling their position in the stock for profit and buying ABBV shares, Cramer remarked:

I like AstraZeneca very much. And that cancer franchise turned out to be a lot stronger than I thought. I think you should hold onto that. AbbVie reports this week. I expect a very good quarter. I like the dividend, but I think AstraZeneca has got a better portfolio at this very moment.

Photo by Artem Podrez on Pexels

AstraZeneca PLC (NASDAQ:AZN) manufactures prescription medicines for oncology, cardiovascular, respiratory, and rare diseases. Oakmark International Fund stated the following regarding AstraZeneca PLC (NASDAQ:AZN) in its fourth quarter 2025 investor letter:

AstraZeneca PLC (NASDAQ:AZN) is one of the largest pharmaceutical companies in the world. It researches, develops and commercializes prescription medicines designed to treat lung and breast cancers, cardiorenal diseases, respiratory problems and other rare diseases. We believe AstraZeneca’s robust on-market portfolio and sector-leading late-stage pipeline provide an attractive growth profile. Moreover, we believe the company can build on its long track record of a productive research and development program, thanks to its innovative culture and exceptional management team. CEO Pascal Soriot is one of the industry’s best executives, and he has cultivated a deep bench of talent, a robust decision-making framework and a differentiated R&D culture that should drive strong growth for years to come, in our view. Recent concerns over United States regulations have overshadowed AstraZeneca’s merits and weighed on the broader pharmaceutical industry. This opened a window for us to purchase shares of this company at a price well below our estimate of its intrinsic value.

While we acknowledge the risk and potential of RDDT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RDDT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.